<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Venous or <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo>, abortion, and the presence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL) define the criteria for the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) </plain></SENT>
<SENT sid="1" pm="."><plain>A <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of antibodies against <z:chebi fb="1" ids="16247">phospholipids</z:chebi> and plasma proteins may influence several coagulation pathways and lead to <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated the presence of antibodies to thrombin (Thr) in patients with aPL and reviewed their clinical manifestations </plain></SENT>
<SENT sid="3" pm="."><plain>IgG and IgM titers of aPL were measured by ELISA (Aesku.Diagnostics, Wendelsheim, Germany) </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus</z:e> <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> (LA) were measured according to the criteria of the Scientific and Standardization Committee of the International Society on <z:mp ids='MP_0005048'>Thrombosis</z:mp> and Haemostasis </plain></SENT>
<SENT sid="5" pm="."><plain>One hundred twenty patients were identified with LA or anticardiolipin (aCL) </plain></SENT>
<SENT sid="6" pm="."><plain>Of the 120 patients, 98 (82%) had primary APS and 22 (18%) had secondary APS </plain></SENT>
<SENT sid="7" pm="."><plain>Further, 76/120 (63%) were suffering from thromboembolic manifestations, mostly <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Anti-thrombin-IgG was detected in 20%, and anti-thrombin-IgM was detected in 23% of the patients </plain></SENT>
<SENT sid="9" pm="."><plain>The presence of anti-thrombin antibodies was closely related to the presence of anti-beta(2)-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi>-I (beta(2)-GP-I) (96%), aCL (97%), and LA (87%), and less well to the presence of anti-phosphatidylserine/prothrombin (Ser/Pro) antibodies (71%) or anti-prothrombin antibodies (Pro) (50%) </plain></SENT>
<SENT sid="10" pm="."><plain>Sixty-seven percent of the patients with anti-Thr-IgG suffered from thromboembolic complications, mostly <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>The rate of <z:mp ids='MP_0005048'>thrombosis</z:mp> was higher for these patients than for patients with anti-beta(2)-GP-I antibodies (37/60, 62%), LA (50/79, 63%), or anti-Ser/Pro antibodies (18/28, 64%) </plain></SENT>
<SENT sid="12" pm="."><plain>Anti-thrombin antibodies were found in 20% of patients with aPL; 67% of these patients were admitted with thrombotic manifestations of APS </plain></SENT>
<SENT sid="13" pm="."><plain>The presence of anti-thrombin antibodies was closely associated with the presence of aCL and anti-beta(2)-GP-I antibodies </plain></SENT>
<SENT sid="14" pm="."><plain>The sensitivity of the test for anti-thrombin antibodies for the diagnosis of APS was higher than the sensitivity of the anti-prothrombin assay and similar to the sensitivity of the anti-Ser/Pro assay </plain></SENT>
</text></document>